The management of cardiovascular disease risk in patients with rheumatoid arthritis

References

• Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken). 2014 Sep;669:1296–1301. Erratum in: Arthritis Care Res (Hoboken). 2015 Jan;67(1):135.
   PubMed Web of Science ®Google Scholar
• Wang H, Li X, Gong G. Cardiovascular outcomes in patients with co-existing coronary artery disease and rheumatoid arthritis: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(14):e19658.
   PubMedGoogle Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;761:17–28.
   PubMed Web of Science ®Google Scholar
• National institute for clinical excellence guidelines: rheumatoid arthritis in adults: management. 2018 July.
   Google Scholar
• Olsen MB, Gregersen I, Sandanger Ø, et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl Sci. 2021 Nov 3;7(1):84–98.
   PubMedGoogle Scholar
• Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35–S61.
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England. PLoS One. 2016 Mar 15;11(3):e0151245.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Davis JM, Roger VL, et al. Improved incidence of cardiovascular disease in patients with incident rheumatoid arthritis in the 2000s: a population-based cohort study. J Rheumatol. 2021;48(9):1379–1387.
   PubMedGoogle Scholar
• Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401.
   PubMedGoogle Scholar
• Kerola AM, Kazemi A, Rollefstad S, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford) (Published online ahead of print). 2022; keac210
   Google Scholar
• Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015 Feb 17;10(2):e0117952.
   PubMedGoogle Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135–1143.
   PubMedGoogle Scholar
• Venetsanopoulou AI, Pelechas E, Voulgari PV, et al. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020 Aug;40(8):1181–1191.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. International society of hypertension global hypertension practice guidelines. Hypertension. 2020 Jun;75(6):1334–1357.
   PubMed Web of Science ®Google Scholar
• Jafri K, Bartels CM, Shin D, et al. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017 Jan;69(1):51–57.
   PubMedGoogle Scholar
• Hadwen B, Stranges S, Barra L. Risk factors for hypertension in rheumatoid arthritis patients-A systematic review. Autoimmun Rev. 2021 Apr;20(4):102786.
   PubMedGoogle Scholar
• Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2015 Jan–Feb;33(1):115–121.
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D, Hermansson M, Ulfgren AK, et al. smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008 Oct;67(10):1488–1492.
   PubMed Web of Science ®Google Scholar
• Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2706–2716.
   PubMed Web of Science ®Google Scholar
• Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014 Sep;13(9):981–1000.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Hopkins AM, Sorich MJ, et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep. 2020 Oct 29;10(1):18634.
   PubMedGoogle Scholar
• Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev. 2006 May;5(5):331–337.
   PubMed Web of Science ®Google Scholar
• Bartoloni E, Alunno A, Bistoni O, et al. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev. 2010 Aug;9(10):701–707.
   PubMedGoogle Scholar
• Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015 Jun;676:1449–1455.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Guan H, Stryker S, et al. OP0101 rheumatoid arthritis disease activity over time and subsequent cardiovascular risks. Ann Rheum Dis. 2021;80:56.
   Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. ESC national cardiac societies; ESC scientific document group. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. circulation. J Am Coll Cardiol. 2019 Sep 10;140(11):e596–e646. Erratum in: Circulation. 2019 Sep 10;140(11):e649-e650. Erratum in: Circulation. 2020 Jan 28;141(4):e60. Erratum in: Circulation. 2020 Apr 21;141(16):e774.
   Google Scholar
• DC G Jr, Lloyd-Jones DM, Bennett G, et al. American college of cardiology/American heart association task force on practice guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49–73. Erratum in: Circulation. 2014 Jun 24;129(25 Suppl 2):S74-5.
   PubMedGoogle Scholar
• van der Leeuw J, van Dieren S, Beulens JW, et al. The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. Heart. 2015 Feb;101(3):222–229.
   PubMedGoogle Scholar
• RB D Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12; 117(6):743–753.
   PubMedGoogle Scholar
• Conroy RM, Pyörälä K, Fitzgerald AP, et al. estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987–1003.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007 Feb 14;297(6):611–619. Erratum in: JAMA. 2007 Apr 4;297(13):1433.
   PubMedGoogle Scholar
• DC G Jr, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;63(25 Pt B):2935–2959. Erratum in: J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3026. 2014 Jul 1.
   PubMedGoogle Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017 May 23;357:j2099.
   PubMedGoogle Scholar
• SCORE2 working group and ESC cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439–2454.
   PubMedGoogle Scholar
• Arts EE, Popa C, Den Broeder AA, et al. performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015 Apr;74(4):668–674.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Rollefstad S, Kitas GD, et al. A trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA). Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One. 2017 Mar 23;12(3):e0174656. Erratum in: PLoS One. 2017 Apr 7;12 (4):e0175605.
   PubMedGoogle Scholar
• Bartels CM, Roberts TJ, Hansen KE, et al. Rheumatologist and primary care management of cardiovascular disease risk in rheumatoid arthritis: patient and provider perspectives. Arthritis Care Res (Hoboken). 2016 Apr;68(4):415–423.
   PubMed Web of Science ®Google Scholar
• Ladak K, Hashim J, Clifford-Rashotte M, et al. Cardiovascular risk management in rheumatoid arthritis: a large gap to close. Musculoskeletal Care. 2018 Mar;16(1):152–157.
   PubMedGoogle Scholar
• Crowson CS, Gabriel SE, Semb AG, et al. Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford). 2017 Jul 1;56(7):1102–1110.
   PubMedGoogle Scholar
• Navarini L, Margiotta DPE, Caso F, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with psoriatic arthritis: an Italian bicentric study. PLoS One. 2018 Oct 11;13(10):e0205506.
   PubMedGoogle Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines [published correction appears in circulation. J Am Coll Cardiol. 2018 [2019 Jun 18];139(25):e1178–e1181]. Circulation. 2019;139(25):e1046-e1081.
   Google Scholar
• Hansen PR, Feineis M, Abdulla J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: a systematic literature review and meta-analysis. Eur J Intern Med. 2019 Apr;62:72–79.
   PubMed Web of Science ®Google Scholar
• Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ. 2021 May 4;373(776).
   PubMedGoogle Scholar
• Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. JAMA Cardiol. 2017 Dec 1 2(12):1332–1340.
   PubMedGoogle Scholar
• Budoff M, Backlund JC, Bluemke DA, et al. The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT/EDIC trials. JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1341–1349.
   PubMedGoogle Scholar
• Kim SH, Lee SH, Kim HR, et al. Cardiovascular disease risk calculators to reflect the subclinical atherosclerosis of coronary artery in rheumatoid arthritis: a pilot study. BMC Rheumatol. 2021 Aug 30; 5(1):39.
   PubMedGoogle Scholar
• Ikdahl E, Rollefstad S, Wibetoe G, et al. Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol. 2016 Sep;43(9):1622–1630.
   PubMed Web of Science ®Google Scholar
• Fine NM, Crowson CS, Lin G, et al. Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography. Ann Rheum Dis. 2014;73(10):1833–1839.
   PubMed Web of Science ®Google Scholar
• Tański W, Gać P, Chachaj A, et al. Left ventricular myocardial strain assessed by cardiac magnetic resonance feature tracking in patients with rheumatoid arthritis. Insights Imaging. 2021;12(1):5.
   PubMedGoogle Scholar
• Wolfe F, Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1471–1479.
   PubMedGoogle Scholar
• Crowson CS, Rollefstad S, Ikdahl E, et al. A trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018 Jan;77(1):48–54.
   PubMed Web of Science ®Google Scholar
• England BR, Baker JF, Sayles H, et al. Body mass index, weight loss, and cause-specific mortality in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Jan;70(1):11–18.
   PubMedGoogle Scholar
• Ellulu MS, Patimah I, Khaza’ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017 Jun;13(4):851–863.
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, GS M, Veldhuijzen van Zanten JJ, et al. Individualised aerobic, and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2013 Nov;72(11):1819–1825.
   PubMed Web of Science ®Google Scholar
• Cooney JK, Ahmad YA, Moore JP, et al. The impact of cardiorespiratory fitness on classical cardiovascular disease risk factors in rheumatoid arthritis: a cross-sectional and longitudinal study. Rheumatol Int. 2019 Oct;39(10):1759–1766.
   PubMedGoogle Scholar
• Sokolove J, Wagner CA, Lahey LJ, et al. Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans. Rheumatology (Oxford). 2016 Nov;55(11):1969–1977.
   PubMed Web of Science ®Google Scholar
• Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2015 Aug;74(8):1509–1514.
   PubMedGoogle Scholar
• Roelsgaard IK, Ikdahl E, Rollefstad S, et al. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology (Oxford). 2020 Aug 1;59(8):1997–2004.
   PubMedGoogle Scholar
• Williams B, Mancia G, Spiering W, et al. ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021–3104. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475.
   PubMedGoogle Scholar
• Panoulas VF, Douglas KM, Milionis HJ, et al. prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007 Sep;46(9):1477–1482.
   PubMed Web of Science ®Google Scholar
• van Breukelen-van der Stoep DF, van Zeben D, Klob, B, et al. Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology (Oxford). 2016 Jul;55(7):1210–1216.
   PubMedGoogle Scholar
• Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013 Dec;65(12):2046–2050.
   PubMedGoogle Scholar
• Giles JT, Wasko MCM, Chung CP, et al. Exploring the lipid paradox theory in rheumatoid arthritis: associations of low circulating low-density lipoprotein concentration with subclinical coronary atherosclerosis. Arthritis Rheumatol. 2019 Sep;71(9):1426–1436.
   PubMed Web of Science ®Google Scholar
• Robertson J, Porter D, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017 Nov;76(11):1949–1952.
   PubMed Web of Science ®Google Scholar
• Danninger K, Hoppe UC, Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis. 2014 Jul;17(6):606–611.
   PubMedGoogle Scholar
• Mach F, Baigent C, Catapano AL, et al., ESC Scientific Document Group. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 [2020 Jan 1];41(1):111–188. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255.
   Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107.
   PubMedGoogle Scholar
• Frostegård J, Ahmed S, Hafström I, et al. Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms. Arthritis Res Ther. 2021 Jan 19;23(1):32.
   PubMedGoogle Scholar
• Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020 Jan;72(1):31–40.
   PubMed Web of Science ®Google Scholar
• Semb AG, Ikdahl E, Wibetoe G, et al. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020 Jul;16(7):361–379.
   PubMed Web of Science ®Google Scholar
• Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev. 2015;2015:536962.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Asghar W, Jamali F. Adverse effects of non-steroidal anti-inflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847.
   PubMed Web of Science ®Google Scholar
• Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognised public health issue. Cureus. 2017 Apr 8;9(4):e1144.
   PubMedGoogle Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011 Nov;50(11):1982–1990.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560–1567.
   PubMed Web of Science ®Google Scholar
• Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007 Nov;157(5):545–559.
   PubMed Web of Science ®Google Scholar
• Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002 Apr 6; 359(9313):1173–1177.
   PubMedGoogle Scholar
• Sun KJ, Liu LL, Hu JH, et al. methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Medicine (Baltimore). 2021 Feb 19;100(7):e24579.
   PubMedGoogle Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011 Nov 1;108(9):1362–1370.
   PubMedGoogle Scholar
• Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011 Aug;38(8):1601–1606.
   PubMedGoogle Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999 Jan 14; 340(2):115–126.
   PubMedGoogle Scholar
• Libby P. Inflammation in atherosclerosis-no longer a theory. Clin Chem. 2021 Jan 8; 67(1):131–142.
   PubMedGoogle Scholar
• Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019 Sep 24; 74(12):1594–1607.
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Pradhan A, et al. CIRT investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019 Feb 21;380(8):752–762.
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Thuren T, et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21;377(12):1119–1131.
   PubMedGoogle Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019 Dec 26; 381(26):2497–2505.
   PubMed Web of Science ®Google Scholar
• Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017 Jul 13;7(1):5346.
   PubMedGoogle Scholar
• Ljung L, Askling J, Rantapää-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther. 2014 Jun 18;16(3):R127.
   PubMedGoogle Scholar
• Chung ES, Packer M, Lo KH, et al. Randomised, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003 Jul 1;107(25):3133–3140.
   PubMedGoogle Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomised etanercept worldwide evaluation (RENEWAL). Circulation. 2004 Apr 6;109(13):1594–1602.
   PubMedGoogle Scholar
• Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005 Mar;4(3):153–161.
   PubMed Web of Science ®Google Scholar
• Sinagra E, Perricone G, Romano C, et al. Heart failure and anti-tumour necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med. 2013 Jul;24(5):385–392.
   PubMedGoogle Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54(12):2134–2144.
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010;128(5):309–310.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019 Jan;461:7–18. Erratum in: J Rheumatol. 2019 Dec;46(12):1648–1649.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019 Jul;71(7):1042–1055.
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Levitan EB, et al. Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2019 Aug;71(8):1004–1018.
   PubMedGoogle Scholar
• Pfizer Inc. News release: Pfizer shares co-primary endpoint results from a post-marketing required safety study of Xeljanz (tofacitinib) in subjects with rheumatoid arthritis (RA). 2021 Jan 27.
   Google Scholar
• Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016 Jun;64(6):1403–1415.
   PubMed Web of Science ®Google Scholar
• Zamani P, Schwartz GG, Olsson AG, et al. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28 ;2(1):e003103. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing
   PubMedGoogle Scholar
• Huo S, Shi W, Ma H, et al. Alleviation of inflammation and oxidative stress in pressure overload-induced cardiac remodeling and heart Failure via IL-6/STAT3 inhibition by raloxifene. Oxid Med Cell Longev. 2021 Mar 20;2021:6699054.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000 Apr 18;101(15):1767–1772.
   PubMed Web of Science ®Google Scholar
• Strang AC, Bisoendial RJ, Kootte RS, et al. pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013 Jul;229(1):174–181.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Hagino O, et al. The effect of sarilumab in combination with DMARDs on fasting glucose and glycosylated hemoglobin in patients with rheumatoid arthritis with and without diabetes [abstract]. Arthritis Rheumatol. 2017;69(suppl):10.
   Google Scholar